Company Description
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.
The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios.
It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry.
The company was founded in 2021 and is based in Heidelberg, Germany.
Contact Details
Address: Im Neuenheimer Feld 584 Heidelberg, 69120 Germany | |
| Phone | 49 6221 3521330 |
| Website | veraxa.com |
Stock Details
| Ticker Symbol | VRXA |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 2079109 |
| ISIN Number | CH1476899161 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christoph Antz Ph.D. | Co-Founder, Lead Director and Chief Executive Officer |
| Carl von Halem | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Christoph Erkel Ph.D. | Chief Scientific Officer |
| Dr. Heinz Schwer M.B.A., Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 10, 2026 | 424B5 | Filing |
| Aug 10, 2026 | 424B5 | Filing |
| Aug 6, 2026 | EFFECT | Notice of Effectiveness |
| Aug 6, 2026 | EFFECT | Notice of Effectiveness |
| Aug 5, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Aug 5, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 31, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Jul 31, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Jul 31, 2026 | 6-K | Report of foreign issuer |
| Jul 27, 2026 | 6-K | Report of foreign issuer |